SETD4: A Potential Drug Target and Biomarker (G54093)

Target Name: SETD4

NCBI ID: G54093

SETD4

SETD4: A Potential Drug Target and Biomarker

Spermidine-associated protein 4 (SETD4) is a gene that encodes a protein involved in DNA repair, specifically homologous recombination (HRC). SETD4 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including DNA replication, repair, and cancer progression.Recent studies have identified SETD4 as a potential drug target and biomarker for various diseases, including cancer.

SETD4 and its functions

SETD4 is a member of the Spermidine-associated protein (SAP) family, which includes other well-known proteins such as DNA repair enzyme, DNA-binding protein, and tumor suppressor protein. The SAP family plays a crucial role in maintaining DNA integrity and has been implicated in various diseases, including cancer.

SETD4 is involved in DNA repair and has been shown to regulate multiple cellular processes, including DNA replication, repair, and homologous recombination (HRC). It has been shown to promote DNA replication by activating the DNA-protein complex that is formed during the G1 phase of the cell cycle.SETD4 also plays a role in repairing damaged DNA by facilitating the formation of a double-stranded break in damaged DNA.

In addition to its role in DNA repair, SETD4 has also been shown to promote the development of cancer. Studies have shown that SETD4 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. High levels of SETD4 have also been associated with poor prognosis in cancer patients.

SETD4 as a drug target

SETD4 has been identified as a potential drug target due to its involvement in various cellular processes that are linked to cancer development. Researchers have shown that inhibiting SETD4 function can lead to the inhibition of various cellular processes that are associated with cancer growth, such as cell proliferation, angiogenesis, and immune evasion.

One of the main targets of SETD4 inhibitors is the PI3K/Akt signaling pathway, which is involved in the regulation of cellular processes that are associated with cancer development. Researchers have shown that the PI3K/Akt signaling pathway is activated by SETD4 and that inhibition of this pathway can lead to the inhibition of SETD4-mediated cellular processes that are associated with cancer growth.

Another potential target of SETD4 inhibitors is the S/N-G2 checkpoint, which is involved in the regulation of cellular processes that are associated with cancer resistance. Researchers have shown that the S/N-G2 checkpoint is activated by SETD4 and that inhibition of this pathway can lead to the inhibition of SETD4-mediated cellular processes that are associated with cancer resistance.

SETD4 as a biomarker

SETD4 has also been shown to be a potential biomarker for various diseases, including cancer. Studies have shown that SETD4 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, research has shown that SETD4 levels are often elevated in cancer patient samples and that these levels can be used as a biomarker for cancer diagnosis and monitoring.

In addition to its potential as a drug target, SETD4 has also been shown to be a potential biomarker for various diseases, including cancer. Studies have shown that SETD4 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, research has shown that SETD4 levels are often elevated in cancer patient samples and that these levels can be used as a biomarker for cancer diagnosis and monitoring.

Conclusion

SETD4 is a gene that encodes a protein involved in DNA repair, specifically homologous recombination

Protein Name: SET Domain Containing 4

Functions: Histone-lysine N-methyltransferase that acts as a regulator of cell proliferation, cell differentiation and inflammatory response (PubMed:31308046). Regulates the inflammatory response by mediating mono- and dimethylation of 'Lys-4' of histone H3 (H3K4me1 and H3K4me2, respectively), leading to activate the transcription of pro-inflammatory cytokines IL6 and TNF-alpha (By similarity). Also involved in the regulation of stem cell quiescence by catalyzing the trimethylation of 'Lys-20' of histone H4 (H4K20me3), thereby promoting heterochromatin formation (PubMed:31308046). Involved in proliferation, migration, paracrine and myogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) (By similarity)

The "SETD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets